3-Dimensional Biocompatible Structure for Regeneration of Body Vessel
A biodegradable rod-shaped structure with irregularities or lumens induces vascular regeneration by supporting fluid flow, addressing the limitations of current treatments for lymphedema and ischemic diseases.
Patent Information
- Application Number
- KR1020230154228
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-11-10
- Filing Date
- 2023-11-09
- Publication Date
- 2026-11-10
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for lymphedema and ischemic diseases due to damaged lymphatic or vascular tissues are limited in efficacy, with a need for regenerative medicine-based solutions that can efficiently regenerate damaged lymph nodes and vessels.
A rod-shaped biodegradable structure with cross-sectional irregularities or lumens is implanted at sites of vessel damage, providing mechanical support and promoting fluid flow through capillary action to induce vascular regeneration.
The structure effectively regenerates lymphatic vessels and blood vessels by stabilizing the vessel wall, preventing re-injury, and promoting fluid flow, offering a potential cure for lymphedema and ischemic diseases.
Smart Images

Figure 112023123889279-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a rod-shaped biocompatible structure that promotes the flow of body fluids through capillary action, and a method for inducing body tube regeneration using the same. Background Technology
[0003] Lymphedema refers to an intractable chronic disease characterized by the abnormal accumulation of lymphatic fluid in the interstitial space of soft tissues due to damage to the lymphatic system. Causes of lymphedema include genetic factors (primary lymphedema), infection, cancer, and traumatic injury (primary lymphedema). In particular, lymphedema is frequently observed in cancer patients due to the destruction of lymph nodes and vessels during cancer treatment. If lymphedema becomes severe, the immune response is impaired, leading to easy infection even from minor injuries and potentially life-threatening complications such as cellulitis and sepsis.
[0004] Symptoms of lymphedema include swelling ranging from localized extremities such as the arms and legs to generalized swelling, accompanied by pain, numbness in the hands and feet, and sclerosis. Once symptoms appear, it is a chronic condition that progresses continuously, and to date, it is classified as an intractable disease for which a fundamental cure is difficult to find.
[0005] The number of lymphedema patients is on the rise every year, with the number of domestic patients increasing by a staggering 62% from 20,999 in 2017 to 34,025 in 2021. Notably, given the high incidence rate following breast cancer, more than 74% of all patients are female. Although the prevalence rate is increasing annually in Korea, current treatments include conservative therapies such as compression and physical therapy, as well as surgical treatments such as lymphovenous anastomosis, lymph node metastasis, and lymph node dissection. However, there are limitations, such as restricted therapeutic efficacy where symptoms improve in only about 50% of patients after surgery, and the difficulty of achieving a complete cure. Therefore, there is a need to develop new regenerative medicine-based treatments that efficiently regenerate damaged lymph nodes and lymphatic vessels to eliminate the root cause of lymphedema.
[0007] Throughout this specification, numerous papers and patent documents are referenced and cited. The disclosures of the cited papers and patent documents are incorporated by reference into this specification in their entirety. This makes the state of the art in which the present invention pertains and the content of the present invention more clearly explained. Prior art literature
[0009] Non-patent literature 1. Danielle H Rochlin et al., The role of adjunct nanofibrillar collagen scaffold implantation in the surgical management of secondary lymphedema: Review of the literature and summary of initial pilot studies J Surg Oncol. 121: 121-128 (2020). The problem to be solved
[0010] The inventors have made diligent research efforts to develop a human implantable structure for tissue regeneration capable of efficiently repairing body vessels, such as lymphatic vessels or vascular tissues, that have been structurally or functionally damaged by various causes including surgery, trauma, cancer, infection, or congenital developmental abnormalities. As a result, the inventors have completed the present invention by discovering that when a rod-shaped biodegradable structure, whose cross-section has a lumen acting as a closed passage for body fluids, specifically lymph or blood, or an irregularity acting as an open passage, is implanted at a site of body vessel damage, it provides mechanical support by acting as a framework in the short term, promotes the smooth flow of body fluids through capillary action, and induces the regeneration of blood vessels, lymph nodes, or lymphatic vessels, thereby enabling the efficient improvement and treatment of various pathological conditions caused by blood leakage, ischemic diseases, lymphedema, and damage to blood vessels or lymphatic vessels.
[0011] Therefore, the objective of the present invention is to provide a human implant for inducing vascular regeneration and a composition for treating lymphedema or ischemic disease comprising the same.
[0012] Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims, and drawings. means of solving the problem
[0014] According to one aspect of the present invention, the present invention provides a human implant for inducing body vessel regeneration, comprising a rod-shaped biodegradable structure, wherein the cross section of the structure comprises one or more irregularities, cavities, or combinations thereof that provide a fluid pathway for body fluid.
[0015] The inventors have made diligent research efforts to develop a human implantable structure for tissue regeneration capable of efficiently repairing body vessels, such as lymphatic vessels or vascular tissues, that have been structurally or functionally damaged by various causes including surgery, trauma, cancer, infection, or congenital developmental abnormalities. As a result, it was discovered that when a rod-shaped biodegradable structure, whose cross-section has a lumen acting as a closed passage for body fluids, specifically lymph or blood, or an irregularity acting as an open passage, or a combination thereof, is implanted at a site of body vessel damage, it can efficiently improve and treat various pathological conditions caused by blood leakage, ischemic diseases, lymphedema, and damage to blood vessels or lymphatic vessels. This is achieved by providing mechanical support by acting as a framework in the short term, promoting the smooth flow of body fluids through capillary action, and inducing the regeneration of blood vessels, lymph nodes, or lymphatic vessels.
[0016] In this specification, the term “body vessel” encompasses any tube-shaped passage lumen tissue that provides a pathway for the movement of body fluids, including, but not limited to, lymphatic vessels, blood vessels, bile ducts, and urethral passages. More specifically, a body vessel that can be regenerated as an implant of the present invention is a blood vessel or a lymphatic vessel.
[0017] In this specification, the term “structure” refers to a tissue engineering structure that serves as a temporary mimetic of phloem tissue by providing a pathway for fluid flow and preventing re-injury to the phloem by providing mechanical support, specifically by providing a pathway for the flow of body fluids, while promoting tissue recovery and regeneration by encapsulating living cells, specifically cells derived from damaged phloem or cells involved in the recovery or regeneration thereof (e.g., stem cells).
[0018] The term “cell attachment” refers to the direct or indirect adsorption of a cell to a substrate or other cells while maintaining its inherent biological activity.
[0019] In this specification, the term “transplant” refers to the process of delivering viable tissue, tissue mimics, cells, active ingredients that aid in tissue regeneration, or artificial structures containing such substances from a donor to a recipient for the purpose of maintaining the functional integrity of the scaffold, tissue, or cells transplanted to the recipient. Accordingly, the terms “transplant” or “implant” have the same meaning as “insert” or “implant.”
[0020] In this specification, the term “biodegradable” means the property of naturally degrading when exposed to a physiological solution of pH 6-8, and specifically means the property of being able to degrade over time by body fluids, degrading enzymes, or microorganisms in the body.
[0021] In this specification, the term “irregularity” refers to a structure in which grooves are formed on a surface by regularly or irregularly intersecting depressions and / or protrusions. These grooves formed in this manner act as open fluid pathways, which can induce the flow of lymph fluid through capillary action.
[0022] According to a specific embodiment of the present invention, the cross-section including the irregularities is a cross-section of an H-beam. In this specification, the term “H-beam” refers to a bar-shaped structure whose cross-section is in the shape of the letter H.
[0023] According to a specific embodiment of the present invention, the cross-section including the irregularities is a radial cross-section. In this specification, the term “radial” refers to a shape in which a plurality of protrusions extend symmetrically or asymmetrically in a spoke-like manner from a center point to the periphery. Here, the space formed between the protrusions extending in a spoke-like manner and adjacent protrusions becomes a groove that serves as an open flow path.
[0024] The rod-shaped biodegradable structure used in the present invention can be applied in a form in which a plurality of structures are twisted together to form a twist or braid.
[0025] In this specification, the term “twist” refers to a shape in which two or more rod-shaped structures are twisted in the same direction of rotation.
[0026] In this specification, the term “braid” refers to a shape in which two or more strands of a rod-shaped structure of three or more strands are intersected and twisted.
[0027] More specifically, the plurality of protrusions are in a point-symmetric relationship with respect to the center point.
[0028] According to a specific embodiment of the present invention, the cross-sectional shape of the inner cavity is circular or polygonal.
[0029] When the structure of the present invention has a lumen, the lumen serves as a closed channel through which lymph fluid can flow. If the lumen is circular, it does not need to be geometrically perfect and may have a curved surface similar to a circle. If the lumen is polygonal, it may be, for example, a triangle, a square, a pentagon, or a hexagon, but is not limited thereto. These polygons may or may not be regular polygons. According to a specific embodiment, the lumen of the polygon has a rectangular or square cross-sectional shape.
[0030] According to the present invention, the structure of the present invention may have a cross-section to which the aforementioned irregularities or lumens are applied alternatively, or it may have a cross-section to which both irregularities and lumens are applied. When both irregularities and lumens are applied, the radial center of the protrusion forming the irregularities and the center of the lumens may or may not coincide. More specifically, the radial center of the protrusion and the lumens have the same center.
[0031] According to a specific embodiment of the present invention, the cross-section of the rod-shaped biodegradable structure of the present invention has a major axis of 0.1 to 3.0 mm and a minor axis of 0.1 to 3.0 mm. If the major axis or the minor axis is less than 0.1 mm, the size of the groove caused by the irregularities is not suitable for the formation of vascular endothelial cells or lymphoid endothelial cells, and if it exceeds 3.0 mm, it causes severe pain to the patient due to the high rigidity of the structure. More specifically, it has a major axis of 0.5 to 1.5 mm and a minor axis of 0.5 to 1.5 mm, and most specifically, it has a major axis of 0.8 to 1.2 mm and a minor axis of 0.6 to 0.8 mm.
[0032] According to a specific embodiment of the present invention, the area of the inner cavity is 0.0025 - 6.25 mm 2 It is. More specifically, 0.01 - 4.0 mm 2 is, and more specifically, 0.1 - 0.5 mm 2 and, more specifically, 0.1 - 0.3 mm 2 is, and most specifically, 0.1 - 0.2 mm 2 am.
[0033] According to a specific embodiment of the present invention, the biodegradable structure of the present invention comprises a biodegradable polymer.
[0034] In this specification, the term “polymer” refers to a synthetic or natural polymer compound in which monomers of the same or different types are sequentially combined. Accordingly, polymers include homopolymers (polymers in which one type of monomer is polymerized) and copolymers prepared by the polymerization of at least two different monomers, and copolymers include copolymers (polymers prepared from two different monomers) and polymers prepared from more than two different monomers. According to the present invention, the biodegradable structure of the present invention may be a structure prepared using a biodegradable or biocompatible polymer as a raw material.
[0035] In this specification, the term “biocompatibility” refers to a property that does not cause short-term or long-term side effects when administered into the body and comes into contact with the cells, tissues, or body fluids of an organ. Specifically, it includes tissue compatibility and blood compatibility, which do not cause tissue necrosis or blood coagulation upon contact with biological tissue or blood, as well as biodegradability, which disappears after a certain period following administration into the body.
[0036] The biodegradable or biocompatible polymers that can be used as raw materials for the biodegradable structure of the present invention include PCL [poly(caprolactone)], HEMA [poly(2-hydroxyethyl methacrylate)], PVA (polyvinyl alcohol, PEO (Polyethyleneoxide), phospholipid, collagen, alipatic polyether, PLA [poly(lactide)], PGA [poly(glycolide)], PDO [poly(dioxanone)]), PBL [poly(butyrolactone)], PVL [poly(valerolactone)], PLGA [poly(lactide-co-glycolide)], PU (polyurethane), fibronectin, vitronectin, poly(L-lysin), poly(L-glutamic acid), poly(aspartic acid), carboxymethyl cellulose, cellulose sulfate, agarose, alginate, carrangeenan, hyaluronic acid, dextran, chitosan, poly(hydroxybutyric acid), poly(alkylene succinate), polyamide, poly(anhydride), poly(ortho-ester), poly(cyano acrylates), polyphosphazene, poly(hydroxyethyl methacrylate), poly(methyl methacrylate), poly(tetrafluoroethylene), poly(dimethylsiloxane), poly(ethyleneoxide-β-propyleneoxide), Poly(vinylmethylether), Includes, but is not limited to, poly(N-alkylacrylamide), decelluarized matrix (dECM), and combinations thereof.More specifically, the biodegradable polymer used in the present invention is one or more selected from the group consisting of PCL [poly(caprolactone)], PLA [poly(lactide)], PGA [poly(glycolide)], PDO [poly(dioxanone)]), PBL [poly(butyrolactone)], PVL [poly(valerolactone)], and PLGA [poly(lactide-co-glycolide)].
[0038] According to a specific embodiment of the present invention, the body fluid is lymph, and the body tube is a lymphatic vessel.
[0039] According to a specific embodiment of the present invention, the body fluid is blood, and the body tube is a blood vessel.
[0040] According to another aspect of the present invention, the present invention provides a composition for treating lymphedema comprising the human implant of the present invention described above as an active ingredient.
[0041] According to another aspect of the present invention, the present invention provides a method for treating lymphedema comprising the step of inserting the human body implant of the present invention described above into the body of a subject.
[0042] In this specification, the term “lymphedema” refers to a condition in which lymphatic tissue is damaged due to various causes such as surgery, trauma, cancer, infection, or congenital developmental abnormalities, thereby hindering the smooth movement of lymphatic fluid; the blocked lymphatic fluid then accumulates excessively in the interstitial space of soft tissues, such as the skin and subcutaneous tissue, resulting in the abnormal expansion of the volume of the arms or legs.
[0043] In this specification, the term “treatment” means (a) inhibition of the progression of a disease, illness, or symptom; (b) alleviation of a disease, illness, or symptom; or (c) elimination of a disease, illness, or symptom. When the composition of the present invention is implanted into a lesion site of a subject, it promotes the smooth flow of lymph fluid that has not circulated and has accumulated in specific soft tissues, and induces the regeneration of damaged lymphatic vessels and lymph nodes, thereby serving to inhibit, eliminate, or alleviate a series of symptoms caused by damage and dysfunction of lymphatic tissue. Accordingly, the composition of the present invention may serve as a treatment for these diseases in itself, or it may be applied as an adjuvant treatment for lymphedema by being implanted in combination with the administration of other pharmacological components (e.g., stem cells capable of differentiating into lymphatic tissue). Accordingly, in this specification, the terms “treatment” or “therapeutic agent” include the meaning of “therapeutic aid” or “therapeutic adjuvant.”
[0044] In this specification, the term “object” includes, without limitation, humans, mice, rats, guinea pigs, dogs, rabbits, cats, horses, cattle, pigs, monkeys, chimpanzees, baboons, or rhesus monkeys. Specifically, the object of the present invention is a human.
[0045] According to another aspect of the present invention, the present invention provides a composition for treating ischemic diseases caused by vascular leakage or vascular damage, comprising the human implant of the present invention described above as an active ingredient.
[0046] According to another aspect of the present invention, the present invention provides a method for treating an ischemic disease caused by vascular leakage or vascular damage, comprising the step of inserting the human implant of the present invention described above into the body of a subject.
[0047] According to the present invention, when the composition of the present invention is implanted into a damaged blood vessel lesion, it stabilizes the blood vessel wall to prevent blood leakage and promotes the regeneration and growth of normal blood vessels, thereby efficiently treating various pathological conditions caused by reduced blood flow, including edema of ischemic tissue, local ischemia, and necrosis of ischemic tissue. Effects of the invention
[0049] The features and advantages of the present invention are summarized as follows:
[0050] (a) The present invention provides a human implant for inducing vascular regeneration and a method for treating lymphedema or ischemic disease using the same.
[0051] (b) The structure of the present invention not only prevents re-injury to body vessels, such as lymphatic vessels or blood vessels, during regeneration by providing appropriate physical strength and mechanical support, but also structurally and functionally mimics body fluid tissue in vivo by utilizing a simple rod structure having irregularities (e.g., H-shaped steel) or a lumen (e.g., tube shape) to promote the flow of body fluids through capillary action.
[0052] (c) The structure of the present invention is implanted in a lesion site and decomposes at an appropriate time after the regeneration of the ducts is complete, so it can be usefully utilized as an efficient treatment means for various pathological conditions caused by blockage of lymphatic fluid flow or reduction of blood flow. Brief explanation of the drawing
[0054] Figure 1 is a schematic diagram showing the process of normalizing lymphatic vessels by applying the lymphatic vessel restoration-inducing biocompatible structure of the present invention. FIG. 2 is a front view of the biocompatible structure of the present invention. Figure 3 is an image obtained by confirming lymphatic flow through ICG (indocyanine green) fluorescent staining 6 weeks after implanting the biocompatible structure of the present invention into a rabbit model. Figure 4 shows the results of extracting tissue implanted with the structure of the present invention from experimental animals, sectioning it in the transverse direction (Figure 4a) and longitudinal direction (Figure 4b), and then performing H&E (hematoxylin & eosin) staining and MT (Masson's trichrome) staining, respectively. Figure 5 is a figure showing the results of immunofluorescence staining targeting LYVE-1 and CD31 on the areas where structures were transplanted in each experimental animal. Specific details for implementing the invention
[0055] The present invention will be described in more detail below through examples. These examples are intended solely to explain the invention more specifically, and it will be obvious to those skilled in the art that the scope of the invention is not limited by these examples according to the gist of the invention.
[0057] Examples
[0058] Preparation Example 1: Preparation of a biocompatible structure for lymphatic vessel restoration
[0059] A 3D printer (RAISE 3D, USA) was used to manufacture a three-dimensional polymer structure, and the 3D printing technique allows for easy adjustment of the size of the three-dimensional structure according to conditions such as the nozzle diameter, temperature, extrusion pressure, and nozzle travel speed. The inventors fabricated a structure having a three-dimensional structure similar to a lymphatic vessel by stacking strands with a height of 0.2 mm and a diameter of 0.4 mm in the form of an H-beam and a tube, respectively, as shown in FIG. 2a. Polycaprolactone (PCL, Polycaprolactone, Sigma-Aldrich, USA) was used as the raw polymer, and for fabrication, the nozzle diameter was set to 0.4 mm, the nozzle temperature to 130°C, the printing speed to 6 mm / s, and the nozzle travel speed to 6 mm / s. With the settings completed, a three-dimensional structure was fabricated in the form of an H-beam and a tube, with diameters of 0.8 mm and 1 mm, and heights of 0.6 mm and 0.8 mm, respectively. Afterward, sterilization was performed with an e-beam before use in the experiment.
[0061] Experimental Example 1: Tensile Strength Evaluation
[0062] The inventors performed a tensile strength evaluation to confirm the physical properties of the lymphatic vessel-like biocompatible structure of the present invention. A universal testing machine (UNITEST M1, Korea) was used to measure tensile strength, and the tensile strength was evaluated by setting the distance between grips to 65 mm and the tensile speed to 50 mm / min.
[0063] Tensile strength evaluation results of H-beam biocompatible structures Sample number Maximum load (kgf) Elastic modulus (MPa) Tensile strength (MPa) 1 0.63 4.40 15.44 2 0.64 5.06 15.68 3 0.63 4.98 15.44 4 0.61 5.16 14.95 5 0.63 5.26 15.44 average 0.628±0.011 4.972±0.337 15.39±0.267
[0064] Tensile strength evaluation results of tubular biocompatible structures Sample number Maximum load (kgf) Elastic modulus (MPa) Tensile strength (MPa) 1 1.07 4.46 16.39 2 1.00 4.15 15.31 3 0.98 4.07 15.01 4 1.14 4.23 17.46 5 1.01 4.04 15.47 average 1.04 ± 0.065 4.19 ± 0.167 15.92 ± 0.998
[0065] As a result of the tensile strength evaluation, the tensile strength of the H-beam biocompatible structure was 15.39 MPa and the tensile strength of the tubular biocompatible structure was 15.92 MPa, indicating that the tubular biocompatible structure has a higher tensile strength. Additionally, the elastic modulus of the H-beam biocompatible structure was 4.90 MPa and the tensile strength of the tubular biocompatible structure was 4.19 MPa, indicating that the H-beam biocompatible structure has higher stiffness.
[0067] Experimental Example 2: Rabbit Model Animal Experiment
[0068] The inventors intended to evaluate whether lymphatic regeneration is induced by the transplantation of the lymphatic-like biocompatible structure of the present invention. The experiment was conducted by dividing New Zealand white rabbits (10 weeks old, female) into a total of four groups: a group in which a lymphatic vessel located in the popliteal fossa was resected by 2 cm and the remaining lymphatic vessel was sutured to the lymph node; a group in which an H-beam shaped structure of the present invention was sutured to the lymph node and lymphatic vessel; a group in which a tubular shaped structure of the present invention was sutured to the lymph node and lymphatic vessel; and a normal lymphatic vessel group.
[0069] Six weeks after suturing, approximately 1cc of 10% ICG (indocyanine green) fluorescent dye was injected subcutaneously into the interdigital area of the foot, and lymphatic flow was examined by contrast imaging of the resected lymphatic vessels and lymph nodes (Figs. 3a and 3b). After sacrificing each experimental animal and extracting tissue from the area where the structure was implanted, the tissue was sectioned transversely and longitudinally, and H&E (hematoxylin & eosin) staining and MN (masson's trichrome) staining (Figs. 4a and 4b) and immunofluorescence staining targeting LYVE-1 (lymphatic vessel endothelial hyaluronic acid receptor 1) and CD31 (cluster of differentiation 31) antigens were performed (Fig. 5).
[0070] By observing that the ICG used for lymphatic flow testing was well visualized from the injection site (foot) to the popliteal lymphatic vessel where the resection was performed, it was confirmed that the fluorescent reagent circulated well through each structure. Through this, it was confirmed that both the H-beam structure and the tubular structure of the present invention can perform the function of alternative lymphatic vessels.
[0071] In addition, through H&E and MT staining, it was observed that when the H-beam shaped structure was implanted, muscle formed around the H-beam structure, and in the case of the tubular shaped structure, collagen formed around the structure. In the case of lymphatic vessels, the area in contact with the internal space where lymph flows is composed of lymphatic endothelial cells, which are wrapped by smooth muscle, while lymphatic capillaries are composed of lymphatic endothelial cells wrapped by collagen fibers. This pattern confirmed that the H-beam shaped structure of the present invention mimics the shape of a lymphatic vessel, and the tubular shaped structure of the present invention mimics the shape of a lymphatic capillary, thereby efficiently inducing regeneration into lymphatic vessels and lymphatic capillaries.
[0072] Since lymphatic vessel formation and regeneration are initiated by lymphoid endothelial cells, lymphoid endothelial cells are an important indicator of lymphatic vessel regeneration. LYVE-1 is a receptor present on lymphoid endothelial cells, and the presence of lymphoid endothelial cells can be confirmed through LYVE-1 staining. Additionally, CD31 is an adhesion molecule primarily present on platelets, leukocytes, and endothelial cells; as it helps endothelial cells adhere and grow, it is an important indicator of angiogenesis and regeneration. As a result of performing immunofluorescence staining targeting LYVE-1 and CD31, it was confirmed that lymphoid endothelial cells were significantly formed around the transplanted structures in both the H-beam and tubular structures, and CD31, which is involved in angiogenesis, was also observed (Fig. 5). Through this, it was confirmed that lymphatic vessel regeneration was efficiently induced in both the H-beam and tubular structures of the present invention.
[0074] Specific parts of the present invention have been described in detail above. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
Claim 1 A human implant for inducing regeneration of a body vessel, comprising a rod-shaped biodegradable structure, wherein the cross section of the structure comprises two or more irregularities that provide a fluid pathway for body fluid, wherein the irregularities are formed on the surface of the structure and act as open fluid pathways to cause fluid flow through capillary action, wherein the irregularities are structured such that grooves are formed on the surface by intersecting depressions and / or protrusions, and wherein the formed grooves act as open fluid pathways to cause fluid flow through capillary action, and wherein the fluid pathway is formed within a lymphatic vessel or blood vessel due to the irregularities. Claim 2 A human body implant according to claim 1, characterized in that the cross-section including the irregularities is an H-beam. Claim 3 A human body implant according to claim 1, characterized in that the cross-section of the structure is radial. Claim 4 delete Claim 5 A human body implant according to claim 1, characterized in that the cross-section has a major axis of 0.1 - 3.0 mm and a minor axis of 0.1 - 3.0 mm. Claim 6 delete Claim 7 A human implant according to claim 1, characterized in that the biodegradable structure comprises one or more biodegradable polymers selected from the group consisting of PCL [poly(caprolactone)], PLA [poly(lactide)], PGA [poly(glycolide)], PDO [poly(dioxanone)]), PBL [poly(butyrolactone)], PVL [poly(valerolactone)], and PLGA [poly(lactide-co-glycolide)]. Claim 8 A human body implant according to claim 1, characterized in that the body fluid is lymph fluid and the body tube is a lymphatic tube. Claim 9 A human body implant according to claim 1, characterized in that the body fluid is blood and the body tube is a blood vessel. Claim 10 delete Claim 11 delete
Citation Information
Patent Citations
endoluminal graft, endoluminal stent, or endoluminal conduit
JP2002501777A
Treatment catheters with thermally insulated regions
US20020082556A1
Method for Surgical Treatment of Occlusive Disease
US20100049237A1
Biodegradable optical fibers and methods of use thereof
US20160245990A1
Medical Implant Porous Scaffold Structure Having Low Modulus
US20170224491A1
